<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Rijke, Y.B. de</title>
    <link>http://repub.eur.nl/res/aut/7983/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Maternal thyroid autoimmunity during pregnancy and the risk of attention deficit/hyperactivity problems in children: The generation r study (Article)</title>
      <link>http://repub.eur.nl/res/pub/38257/</link>
      <pubDate>2012-02-01T00:00:00Z</pubDate>
      <description>Background: Maternal thyroid status and autoimmunity during pregnancy have been associated with impaired development of the offspring in animal and human studies. Our objective was to examine whether elevated titers of maternal thyroid peroxidase antibodies (TPOAbs) in early pregnancy increased the risk of cognitive impairment and problem behavior in preschool children. Second, we aimed at exploring to what extent any effect on child behavior was mediated by maternal thyroid parameters during pregnancy. Methods: In the Generation R Study, a population-based cohort of 3139 children and their mothers, we measured maternal thyroid parameters (thyrotropin [TSH], free Thyroxine, and TPOAbs) at 13.5±1.8 weeks of gestation. Children's verbal and nonverbal cognitive functioning was measured at 2.5 years using the Language Development Survey and the Parent Report of Children Abilities. At 3 years, children's behavior was assessed using the Child Behavior Checklist. Results: Elevated titers of TPOAbs during pregnancy did not predict the verbal and nonverbal cognitive functioning of the children. However, elevated titers of TPOAbs in mothers were associated with externalizing problems in children (odds ratio [OR]=1.64, 95% confidence interval [CI]: 1.17-2.29, p=0.004). In particular, children of TPOAb-positive mothers were at a higher risk of attention deficit/hyperactivity problems (OR=1.77, 95% CI: 1.15-2.72, p=0.01). To explore whether the effect of maternal TPOAbs on child problem behavior was mediated by maternal thyroid parameters, we added maternal TSH to the model. After correcting for TSH, the effect of TPOAbs on externalizing problems was attenuated slightly but remained significant (OR=1.56, 95% CI: 1.14, 2.14, p=0.005). Conclusions: Our findings imply that the elevated titers of TPOAbs during pregnancy impact children's risk of problem behavior, in particular, attention deficit/hyperactivity. The observed effect is only partially explained by maternal TSH levels. These findings may point to a specific mechanism of Attention Deficit/Hyperactivity Disorder in children. Nevertheless, we can only speculate about public health implication of the study, as there is no specific treatment for TPOAb-positive pregnant women with normal thyroid function. Further investigation is needed to explore whether TPOAb-positive pregnant women and their children can benefit from close monitoring and early detection of developmental delay in populations at risk. </description>
    </item> <item>
      <title>Copeptin does not accurately predict disease severity in imported malaria (Article)</title>
      <link>http://repub.eur.nl/res/pub/35016/</link>
      <pubDate>2012-01-06T00:00:00Z</pubDate>
      <description>Background: Copeptin has recently been identified to be a stable surrogate marker for the unstable hormone arginine vasopressin (AVP). Copeptin has been shown to correlate with disease severity in leptospirosis and bacterial sepsis. Hyponatraemia is common in severe imported malaria and dysregulation of AVP release has been hypothesized as an underlying pathophysiological mechanism. The aim of the present study was to evaluate the performance of copeptin as a predictor of disease severity in imported malaria. Methods. Copeptin was measured in stored serum samples of 204 patients with imported malaria that were admitted to our Institute for Tropical Diseases in Rotterdam in the period 1999-2010. The occurrence of WHO defined severe malaria was the primary end-point. The diagnostic performance of copeptin was compared to that of previously evaluated biomarkers C-reactive protein, procalcitonin, lactate and sodium. Results: Of the 204 patients (141 Plasmodium falciparum, 63 non-falciparum infection), 25 had severe malaria. The Area Under the ROC curve of copeptin for severe disease (0.66 [95% confidence interval 0.59-0.72]) was comparable to that of lactate, sodium and procalcitonin. C-reactive protein (0.84 [95% CI 0.79-0.89]) had a significantly better performance as a biomarker for severe malaria than the other biomarkers. Conclusions: C-reactive protein but not copeptin was found to be an accurate predictor for disease severity in imported malaria. The applicability of copeptin as a marker for severe malaria in clinical practice is limited to exclusion of severe malaria. </description>
    </item> <item>
      <title>Thyroid status in a large cohort of patients with mental retardation: The TOP-R (Thyroid Origin of Psychomotor Retardation) study (Article)</title>
      <link>http://repub.eur.nl/res/pub/31222/</link>
      <pubDate>2011-09-01T00:00:00Z</pubDate>
      <description>Objective Abnormalities in thyroid state may affect development and function of the brain and result in mental retardation (MR). Thyroid parameters have not been systematically investigated in institutionalized MR subjects. The objective is to measure thyroid parameters in a novel cohort of 946 institutionalized subjects. Design The TOP-R (Thyroid Origin of Psychomotor Retardation) study is a cross-sectional nation-wide multicentre study. Patients Subjects with unexplained MR. Results The majority of the MR subjects had thyroid parameters within the reference range used in our laboratory. Antiepileptic drugs (AEDs) use affected thyroid hormones (T4: 102·1 ± 1·2 vs 83·9 ± 1·2 nmol/l, P &lt; 1 × 10-24; FT4: 18·0 ± 0·2 vs 16·1 ± 0·2 pmol/l, P &lt; 1 × 10-9; T3: 1·72 ± 0·02 vs 1·57 ± 0·02 nmol/l, P &lt; 1 × 10-9; and rT3: 0·37 ± 0·01 vs 0·27 ± 0·01 nmol/l, P &lt; 1 × 10-28in subjects without vs with AEDs). The prevalence of unrecognized primary hypothyroidism and hyperthyroidism was 5·2% and 2·8%, respectively. Conclusions We report thyroid parameters in a cohort of institutionalized subjects with MR. Our findings substantiate the fact that AEDs affect thyroid hormone levels. Future studies will be employed to investigate genetic causes of MR related to abnormalities in thyroid hormone homeostasis. </description>
    </item> <item>
      <title>Maternal thyroid function during pregnancy and behavioral problems in the offspring: The generation R study (Article)</title>
      <link>http://repub.eur.nl/res/pub/26472/</link>
      <pubDate>2011-05-01T00:00:00Z</pubDate>
      <description>Maternal thyroid function during pregnancy is implicated in the neurodevelopment of the offspring, yet little is known about the effect of maternal thyroid parameters on the behavior of children. We investigated the association of maternal thyroid function during the first half of pregnancy with parent-reported problem behavior of the offspring up to age of 3 y. In the Generation R study, a population-based cohort of 3736 children and their mothers, data on maternal thyroid function and child's behavior were examined. The degree of internalizing and externalizing problems in the children were assessed with the Child Behavior Checklist at ages 11/2 and 3 y. Higher levels of maternal TSH during pregnancy predicted a higher externalizing scores in children at 11/2 and 3 y (B = 0.22 per SD of TSH; 95% CI: 0.04, 0.40; B = 0.10 per SD for internalizing scores; 95% CI:-0.01, 0.21). Maternal free thyroxine (T4) and total T4 were not associated with internalizing or externalizing scores of children. The linear relationship with more externalizing scores was across the range of TSH; this implies that subtle impairments of maternal thyroid function may affect the child. The results suggest that thyroid function is crucial for fetal brain development, which determines problem behavior later in life. Copyright </description>
    </item> <item>
      <title>Spuriously high free thyroxine values in familial dysalbuminemic hyperthyroxinemia (Article)</title>
      <link>http://repub.eur.nl/res/pub/33527/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Reference values for serum creatinine in children younger than 1 year of age (Article)</title>
      <link>http://repub.eur.nl/res/pub/28128/</link>
      <pubDate>2010-10-01T00:00:00Z</pubDate>
      <description>Reliable reference values of enzymatically assayed serum creatinine categorized in small age intervals are lacking in young children. The aim of this study was to determine reference values for serum creatinine during the first year of life and study the influence of gender, weight and height on these values. Serum creatinine determinations between 2003 and 2008 were retrieved from the hospital database. Strict exclusion criteria ensured the selection of patients without kidney damage. Correlation analysis was performed to evaluate the relation between height, weight and serum creatinine; the Mann-Whitney test was used to evaluate the relation between gender and serum creatinine. A broken stick model was designed to predict normal serum creatinine values. Mean serum creatinine values were found to decrease rapidly from 55 μmol/L on day 1 to 22 μmol/L in the second month of life; they then stabilized at 20 μmol/L until the seventh month, followed by a slight increase. No significant relation was found between serum creatinine and gender, weight and height. We present here reference values of serum creatinine in infants not at risk of decreased renal function. The absence of a relationship with gender, weight and height confirms that height-based equations to estimate glomerular filtration rate are less useful in patients of this age group. </description>
    </item> <item>
      <title>Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: The generation R study (Article)</title>
      <link>http://repub.eur.nl/res/pub/27484/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>Context: Thyroid hormones are essential for neurodevelopment from early pregnancy onward. Yet population-based data on the association between maternal thyroid function in early pregnancy and children's cognitive development are sparse. Objective: Our objective was to study associations of maternal hypothyroxinemia and of early pregnancy maternal TSH and free T4(FT4) levels across the entire range with cognitive functioning in early childhood. Design and Setting: We conducted a population-based cohort in The Netherlands. Participants: Participants included 3659 children and their mothers. Main Measures: In pregnant women with normal TSH levels at 13 wk gestation (SD = 1.7), mild and severe maternal hypothyroxinemia were defined as FT4concentrations below the 10th and 5th percentile, respectively. Children's expressive vocabulary at 18 months was reported by mothers using the MacArthur Communicative Development Inventory. At 30 months, mothers completed the Language Development Survey and the Parent Report of Children's Abilities measuring verbal and nonverbal cognitive functioning. Results: Maternal TSH was not related to the cognitive outcomes. An increase in maternal FT4predicted a lower risk of expressive language delay at 30 months only. However, both mild and severe maternal hypothyroxinemia was associated with a higher risk of expressive language delay across all ages [odds ratio (OR) = 1.44; 95% confidence interval (CI) = 1.09-1.91; P = 0.010 and OR = 1.80; 95% CI = 1.24-2.61; P = 0.002, respectively]. Severe maternal hypothyroxinemia also predicted a higher risk of nonverbal cognitive delay (OR = 2.03; 95% CI = 1.22-3.39; P = 0.007). Conclusions: Maternal hypothyroxinemia is a risk factor for cognitive delay in early childhood. Copyright </description>
    </item> <item>
      <title>Diagnostic value of urinary dysmorphic erythrocytes in clinical practice (Article)</title>
      <link>http://repub.eur.nl/res/pub/28614/</link>
      <pubDate>2010-07-01T00:00:00Z</pubDate>
      <description>Background: In clinical practice, discriminating between glomerular and nonglomerular causes of hematuria is often difficult. Dysmorphic red blood cells (dRBC) in the urinary sediment are claimed to be effective, but the cutoff points in the literature vary. This follow-up study aimed to determine the diagnostic value of dRBC. Methods: We investigated 134 hematuria patients in the departments of nephrology and urology. To diagnose the origin of hematuria, urological and/or nephrological examination was performed and the %dRBC identified by microscopy. Follow-up was performed after 3.5 years. Results: The cause of hematuria was proven in 68 patients (35% glomerular; 65% nonglomerular). Patients with glomerular disease had significantly more albuminuria and dRBC than patients with nonglomerular disease, but the %dRBC ranged from 1 to 50% and no optimal cutoff could be identified. Logistic regression analysis showed that %dRBC had a predicted probability to diagnose glomerular disease of 77.9% (area under the curve, AUC, 0.85). When %dRBC was combined with other risk factors such as serum creatinine, sex, age, dipstick erythrocyte or proteinuria score and number of casts, the predictive probability increased to 90.6% (AUC 0.97). Follow-up of the included patients showed no benefit of dRBC to identify patients at risk for glomerular disease. Conclusions: The diagnostic value of routinely collected urinary dRBC to diagnose glomerular disease in patients presenting with hematuria is modest. However, including dRBC with other variables, such as age and erythrocyte score on dipstick testing may increase the sensitivity, but needs to be confirmed in another, preferably larger, population. Copyright </description>
    </item> <item>
      <title>Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes (Article)</title>
      <link>http://repub.eur.nl/res/pub/17896/</link>
      <pubDate>2009-11-27T00:00:00Z</pubDate>
      <description>Objective: To investigate the effects of unacylated ghrelin (UAG) and co-administration of acylated ghrelin (AG) and UAG in morbid obesity, a condition characterized by insulin resistance and low GH levels. Design and method: Eight morbidly obese non-diabetic subjects were treated with either UAG 200 μg, UAG 100 μg in combination with AG 100 μg (Comb) or placebo in three episodes of 4 consecutive days in a double-blind randomized crossover design. Study medication was administered as daily single i.v. bolus injections at 0900 h after an overnight fast. At 1000 h, a standardized meal was served. Glucose, insulin, GH, free fatty acids (FFA) and ghrelin were measured up to 4 h after administration. Results: Insulin concentrations significantly decreased after acute administration of Comb only, reaching a minimum at 20 min: 58.2 ± 3.9% of baseline versus 88.7 ± 7.2 and 92.7± 2.6% after administration of placebo and UAG respectively (P&lt;0.01). After 1 h, insulin concentration had returned to baseline. Glucose concentrations did not change after Comb. However, UAG administration alone did not change glucose, insulin, FFA or GH levels. Conclusion: Co-administration of AG and UAG as a single i.v. bolus injection causes a significant decrease in insulin concentration in non-diabetic subjects suffering from morbid obesity. Since glucose concentration did not change in the first hour after Comb administration, our data suggest a strong improvement in insulin sensitivity. These findings warrant studies in which UAG with or without AG is administered for a longer period of time. Administration of a single bolus injection of UAG did not influence glucose and insulin metabolism.</description>
    </item> <item>
      <title>Clinical outcome 5 to 18 years after the Fontan operation performed on children younger than 5 years (Article)</title>
      <link>http://repub.eur.nl/res/pub/24451/</link>
      <pubDate>2009-07-01T00:00:00Z</pubDate>
      <description>Objective: This study assessed clinical condition at midterm follow-up after total cavopulmonary connection for a functionally univentricular heart performed on children younger than 5 years. Methods: Thirty-four Fontan patients (median age 10.4 years, range 6.8-20.7 years, 22 boys, median follow-up 7.8 years, 5.0-17.8 years) underwent electrocardiography, Holter monitoring, bicycle exercise testing, cardiac magnetic resonance imaging, and N-terminal prohormone brain natriuretic peptide (NT-pro-BNP) analysis. Results: Twenty-three patients (68%) were in sinus rhythm. Holter monitoring demonstrated normal mean heart rate, low maximal heart rate, and no clinically significant arrhythmias or sinus node dysfunction. With maximal bicycle ergometry (n = 19), maximum workload (60% of normal), maximum heart rate (90% of normal), and maximal oxygen uptake (69% of normal) were all significantly lower in the Fontan group than in a control group (P &lt; .001). Variables of submaximal exercise indicated less efficient oxygen uptake during exercise in all Fontan patients. Ejection fraction was lower than in control subjects (59% ± 13% vs 69% ± 5%, P &lt; .001). Mean end-diastolic and end-systolic volumes and ventricular mass were higher than in control subjects (P &lt; .001). Mean NT-pro-BNP levels were increased relative to reference values, but only 8 patients had levels above the upper reference limit. Conclusion: At midterm follow-up, Fontan patients were in acceptable clinical condition, with preserved global ventricular function, moderately decreased exercise capacity, and NT-pro-BNP levels within reference range. Systemic ventricular mass was elevated, however, suggesting contractility-afterload mismatch. Long-term consequences for ventricular function merit further investigation. </description>
    </item> <item>
      <title>Effects of therapy with [177Lu-DOTA0,Tyr 3]octreotate on endocrine function (Article)</title>
      <link>http://repub.eur.nl/res/pub/24163/</link>
      <pubDate>2009-06-03T00:00:00Z</pubDate>
      <description>Purpose: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues is a novel therapy for patients with somatostatin receptor-positive tumours. We determined the effects of PRRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate) on glucose homeostasis and the pituitary-gonadal, pituitary-thyroid and pituitary-adrenal axes. Methods: Hormone levels were measured and adrenal function assessed at baseline and up to 24 months of follow-up. Results: In 35 men, mean serum inhibin B levels were decreased at 3 months post-therapy (205 ± 16 to 25 ± 4 ng/l, p &lt; 0.05) and follicle-stimulating hormone (FSH) levels increased (5.9 ± 0.5 to 22.7 ± 1.4 IU/l, p &lt; 0.05). These levels returned to near baseline levels. Total testosterone and sex hormone binding globulin (SHBG) levels decreased (15.0 ± 0.9 to 10.6 ± 1.0 nmol/l, p &lt; 0.05 and 61.8 ± 8.7 to 33.2 ± 3.7 nmol, p &lt; 0.05), respectively, whereas non-SHBG-bound T did not change. An increase (5.2 ± 0.6 to 7.7 ± 0.7 IU/l, p &lt; 0.05) of luteinizing hormone (LH) levels was found at 3 months of follow-up returning to baseline levels thereafter. In 21 postmenopausal women, a decrease in levels of FSH (74.4 ± 5.6 to 62.4 ± 7.7 IU/l, p &lt; 0.05) and LH (26.8 ± 2.1 to 21.1 ± 3.0 IU/l, p &lt; 0.05) was found. Of 66 patients, 2 developed persistent primary hypothyroidism. Free thyroxine (FT4) levels decreased (17.7 ± 0.4 to 15.6 ± 0.6 pmol/l, p &lt; 0.05), whereas thyroid-stimulating hormone (TSH) and triiodothyronine (T3) levels did not change. Reverse triiodothyronine (rT3) levels decreased (0.38 ± 0.03 to 0.30 ± 0.01 nmol/l, p &lt; 0.05). Before and after therapy adrenocorticotropic hormone (ACTH) stimulation tests showed an adequate response of serum cortisol (&gt; 550 nmol/l, n = 18). Five patients developed elevated HbA1clevels (&gt; 6.5%). Conclusion: In men177Lu-octreotate therapy induced transient inhibitory effects on spermatogenesis, but non-SHBG-bound T levels remained unaffected. In the long term, gonadotropin levels decreased significantly in postmenopausal women. Only a few patients developed hypothyroidism or elevated levels of HbA1c. Therefore, PRRT with177Lu-octreotate can be regarded as a safe treatment modality with respect to short-and long-term endocrine function.</description>
    </item> <item>
      <title>Assessment of biventricular functional reserve and NT-proBNP levels in patients with RV volume overload after repair of tetralogy of Fallot at young age (Article)</title>
      <link>http://repub.eur.nl/res/pub/24381/</link>
      <pubDate>2009-04-17T00:00:00Z</pubDate>
      <description>Purpose: To assess biventricular functional reserve (FR), NT-proBNP levels and exercise performance, in relation to right ventricular volume in patients with pulmonary regurgitation (PR) after repair of tetralogy of Fallot (TOF) at young age. Methods: In 53 TOF patients (maximum age at repair 2.0 years, interval since repair 15 (5) years) without residual lesions except PR, biventricular FR (derived from magnetic resonance imaging with dobutamine stress), NT-proBNP levels, maximal workload, and peak oxygen uptake were assessed. Results: Mean right ventricular end-diastolic volume was 140(38) ml/m2. Median pulmonary regurgitant fraction was 37% (range 0-57%). Biventricular systolic stress response was normal: mean (SD) ESV decreased (ΔRVESV - 17(8) ml/m2, ΔLVESV - 11(5)), SV increased (ΔRVSV + 12(9) ml/m2, ΔLVSV + 9(6)), FR was positive in all (RV-FR + 11(5)%, LV-FR + 13(6)). No serious adverse effects to dobutamine were encountered. NT-proBNP was increased in 2 patients. Median level was 10 pmol/L (range 2-42). NT-proBNP correlated with PR-percentage but not with right ventricular size. High-risk levels of NT-proBNP indicated a smaller RV-FR and a smaller decrease of biventricular ESV. Mean (SEM) VO2maxwas 96(3)%, mean Workloadmax89(2)% of predicted. Conclusion: At mid to long term follow-up overall NT-proBNP levels are normal and biventricular functional reserve and exercise tolerance are well preserved in TOF repaired at young age, irrespective of RV volume. This questions the validity of isolated PR or RV volume criteria for pulmonary valve replacement in this group. Low-dose dobutamine stress testing is well tolerated and may be a useful additional tool for clinical decision making. </description>
    </item> <item>
      <title>Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies (Article)</title>
      <link>http://repub.eur.nl/res/pub/18494/</link>
      <pubDate>2009-02-01T00:00:00Z</pubDate>
      <description>Context: A 56-yr-old woman presented with acromegaly, a pulmonary mass, and elevated levels of GHRH, GH, and IGF-I. Histological examination revealed a bronchial carcinoid with positive staining for GHRH. Somatostatin analogs (SAs) can play an important role in the treatment of neuroendocrine tumors, dependent on the somatostatin receptor subtype (sst) expression pattern. The sst pattern in bronchial carcinoids and effects of SAs have not been extensively investigated, particularly not for the recently developed universal SA SOM230 (Pasireotide) that has high affinity for sst1, 2, 3, and 5. Objective: Our objective was to investigate the in vivo response of a GHRH-producing bronchial carcinoid to octreotide (OCT), its sst-expression profile, and in vitro responses to different SAs, including SOM230. Methods: In vivo, 50 μg OCT was administered, and plasma GH and GHRH responses were determined. In vitro, the expression of ssts was analyzed by quantitative PCR. Furthermore, the effects of SOM230 and OCT on GHRH secretion were evaluated in primary cell cultures of the carcinoid tissue. Results: In vivo, OCT administration fully suppressed GH and GHRH levels. In vitro, sst 1 mRNA was most abundant, followed by sst2 and sst 5. Both SOM230 and OCT inhibited GHRH production dose dependently (SOM230 100 nM vs. control, P = 0.01; OCT 110 nM vs. control, P = 0.05). Conclusions: In this case of a GHRH-producing bronchial carcinoid, we demonstrated that SOM230 was a potent inhibitor of GHRH production in vitro and was at least equally potent compared with OCT. Therefore, SOM230 may be a potential therapeutic agent to control GHRH secretion in ectopic acromegaly.</description>
    </item> <item>
      <title>Organic anion transporter 1B1: An important factor in hepatic thyroid hormone and estrogen transport and metabolism (Article)</title>
      <link>http://repub.eur.nl/res/pub/15918/</link>
      <pubDate>2008-09-01T00:00:00Z</pubDate>
      <description>Sulfation is an important pathway in the metabolism of thyroid hormone and estrogens. Sulfation of estrogens is reversible by estrogen sulfatase, but sulfation of thyroid hormone accelerates its degradation by the type 1 deiodinase in liver. Organic anion transporters (OATPs) are capable of transporting iodothyronine sulfates such as T4 sulfate (T 4S), T3S, and rT3S or estrogen sulfates like estrone sulfate (E1S), but the major hepatic transporter for these conjugates has not been identified. A possible candidate is OATP1B1 because model substrates for this transporter include the bilirubin mimic bromosulfophthalein (BSP) and E1S, and it is highly and specifically expressed in liver. Therefore, OATP1B1-transfected COS1 cells were studied by analysis of BSP, E1S, and iodothyronine sulfate uptake and metabolism. Two Caucasian populations (155 blood donors and 1012 participants of the Rotterdam Scan Study) were genotyped for the OATP1B1-Val174Ala polymorphism and associated with bilirubin, E1S, and T4S levels. OATP1B1-transfected cells strongly induced uptake of BSP, E1S, T4S, T3S, and rT3S compared with mocktransfected cells. Metabolism of iodothyronine sulfates by cotransfected type 1 deiodinase was greatly augmented in the presence of OATP1B1. OATP1B1-Val174 showed a 40% higher induction of transport and metabolism of these substrates than OATP1B1-Ala174. Carriers of the OATP1B1-Ala174 allele had higher serum bilirubin, E1S, and T 4S levels. In conclusion, OATP1B1 is an important factor in hepatic transport and metabolism of bilirubin, E1S, and iodothyronine sulfates. OATP1B1-Ala174 displays decreased transport activity and thereby gives rise to higher bilirubin, E1S, and T4S levels in carriers of this polymorphism.</description>
    </item> <item>
      <title>Cardiovascular risk factors in parents of short children born small for gestational age (Article)</title>
      <link>http://repub.eur.nl/res/pub/28853/</link>
      <pubDate>2008-07-01T00:00:00Z</pubDate>
      <description>Small for gestational age (SGA) children have a higher prevalence of cardiovascular risk factors at a young age. It is not known whether this increased risk is caused by their size at birth, a familial predisposition for cardiovascular disease or smallness at birth or a combination of these factors. The cardiovascular risk profile of parents of SGA children is unknown. We compared anthropometry, blood pressure, fasting serum lipid, glucose, and insulin levels of 482 parents (mean age 41 y) and 286 short SGA children with age- and sex-matched references. We also investigated whether these parameters correlated between parents and their offspring. Mothers had higher systolic blood pressure, fathers had a higher body mass index and parents had more frequently high fasting glucose levels than age- and sex-matched references. Children had significantly higher systolic and diastolic blood pressure than sex- and height-matched references. Twenty-four percent (mothers) and 10% (fathers) were born SGA but they did not have more cardiovascular risk factors than those born appropriate for gestational age. Cardiovascular risk factors did not correlate between parents and children. In conclusion, parents of short SGA children have a modest increase in some cardiovascular risk factors but risk factors did not correlate between parents and children. Copyright </description>
    </item> <item>
      <title>Point-of-care creatinine testing in children at risk for sudden deterioration of renal function (Article)</title>
      <link>http://repub.eur.nl/res/pub/36852/</link>
      <pubDate>2007-11-11T00:00:00Z</pubDate>
      <description>Background: Point-of-care testing for creatinine blood concentrations may be useful in predicting the onset of recurrent conditions threatening renal function in children at home. Our aim was to evaluate two point-of-care systems for creatinine testing vs. an automated creatinine assay. Methods: Twenty patients aged between 2 months and 17 years were randomly selected. Capillary blood specimens were taken for two point-of-care tests (Reflotron and i-STAT), and the results were compared to the routine enzymatic creatinine assay on a Hitachi 912 analyser using material collected simultaneously. Results: The mean difference in creatinine concentration between the Reflotron and the Hitachi 912 and i-STAT and Hitachi 912 test was -16 and 4 μmol/L, respectively. The slope of the Passing-Bablok method comparison was 0.95 (95% CI 0.87-1.06) and 0.96 (95% CI 0.90-1.00) for the Reflotron and i-STAT test, respectively. Conclusions: The blood creatinine concentrations measured using the Reflotron and the i-STAT device correlated well with those from the routine assay, especially in the concentration range up to 500 μmol/L. Both systems are good options for point-of-care creatinine testing in capillary blood. However, the i-STAT seems the better option for monitoring at home given its greater ease of use. </description>
    </item> <item>
      <title>Renal Function and Size at Young Adult Age After Intrauterine Growth Restriction and Very Premature Birth (Article)</title>
      <link>http://repub.eur.nl/res/pub/35900/</link>
      <pubDate>2007-10-01T00:00:00Z</pubDate>
      <description>Background: Premature birth and intrauterine growth restriction may increase the risk of developing renal disease at adult age. Renal function may already be impaired at young adult age. Study Design: Cross-sectional study. Setting &amp; Participants: Very premature individuals (gestational age &lt; 32 weeks) recruited from Project on Premature and Small for Gestational Age Infants and full-term-born controls (37 to 42 weeks) recruited from a children's hospital in Rotterdam, The Netherlands. All individuals were 20 years of age at the time of study. Predictors: Gestational age and birth weight: premature and small for gestational age (SGA; n = 23), premature and appropriate for gestational age (n = 29), and controls (n = 30). Outcomes &amp; Measurements: Glomerular filtration rate (GFR), effective renal plasma flow (ERPF), and filtration fraction before and after renal stimulation with low-dose dopamine infusion and oral amino-acid intake. Urine albumin and renal ultrasound. Results: Height, weight, kidney length and volume, GFR, and ERPF were significantly lower in the SGA group than in controls. After adjustment for body surface area, GFR did not differ significantly among groups. Mean ERPF was 71 mL/min/1.73 m2(95% confidence interval [CI], 3 to 139) less, but filtration fraction was only 1.3% (95% CI, -0.3 to 3.0) greater, in the SGA group than controls. Renal stimulation significantly increased GFR and ERPF and decreased filtration fraction in all groups. After renal stimulation, ERPF was 130 mL/min/1.73 m2(95% CI, 21 to 238) greater in the SGA group than controls, but GFR and filtration fraction did not differ significantly among groups. Microalbuminuria was present in 2 patients (8.7%) in the SGA group, but none in the appropriate-for-gestational-age group or controls. Renal function correlated with renal size. Limitations: Small sample size. Conclusions: Our findings do not fully support the hypothesis that preterm birth in combination with intrauterine growth restriction contributes to renal function alterations at young adult age. Larger studies are needed to evaluate this hypothesis. </description>
    </item> <item>
      <title>Effect of growth hormone therapy on serum adiponectin and resistin levels in short, small-for-gestational-age children and associations with cardiovascular risk parameters. (Article)</title>
      <link>http://repub.eur.nl/res/pub/14097/</link>
      <pubDate>2007-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Adiponectin and resistin are fat cell-derived hormones, which are thought to be respectively protective and disadvantageous with regard to the development of cardiovascular disease and diabetes mellitus type 2. Low birth weight has been associated with increased risks for the development of these diseases. In short, small-for-gestational-age (SGA) children, GH therapy has several positive effects regarding cardiovascular risk factors. On the other hand, concern has been expressed about the effects of GH therapy on insulin sensitivity. METHODS: We measured adiponectin and resistin levels in 136 short prepubertal children born SGA and their association with cardiovascular risk parameters and growth factors. Also, we compared the levels with normal-statured controls. The effect of GH treatment was evaluated in 50 short SGA children vs. baseline and vs. an untreated sex- and age-matched SGA control group. RESULTS: Short SGA children had similar adiponectin and lower resistin levels, compared with normal-statured controls. In GH-treated SGA children, neither adiponectin nor resistin levels changed significantly during 2 yr of GH treatment. Compared with untreated sex- and age-matched SGA controls, GH-treated SGA children had similar adiponectin and lower resistin levels. Adiponectin correlated inversely with age but not any cardiovascular risk parameter or growth factor. Higher IGF-I levels in GH-treated children were associated with lower resistin levels. CONCLUSIONS: Compared with normal-statured controls, short prepubertal SGA children had similar adiponectin and lower resistin levels. Two years of GH treatment had no effect on their adiponectin and resistin levels.</description>
    </item> <item>
      <title>Point-of-care C-reactive protein testing in Febrile Children in General Practice (Article)</title>
      <link>http://repub.eur.nl/res/pub/9251/</link>
      <pubDate>2006-01-01T00:00:00Z</pubDate>
      <description>Background: Point-of-care testing for C-reactive protein (CRP) may be helpful in differentiating viral from bacterial infection. Such a device should give results comparable to laboratory testing. The aim was to evaluate two point-of-care CRP tests (Nycocard and QuikRead) in febrile children in general practice, compared to a reference immunoturbidimetric assay. Methods: Cross-sectional study of febrile children aged 3 months to 6 years presented to a general practice out-of-hours service. Children were visited at home, where blood was taken for the tests, within 24 hours of presentation. The Nycocard test was performed at home, whereas the QuikRead and reference test were performed in the laboratory. Results: 76 children were enrolled. All three CRP tests were performed in 59 children. The mean difference between the reference test and Nycocard and QuikRead was 0.6 mg/L and –6.1 mg/L, respectively. The slopes of the Passing and Bablok regression were 0.95 (95% CI 0.9-1.0) and 0.83 (95% CI 0.81-0.85) for Nycocard and QuikRead, respectively. Conclusion: Up to a concentration of 160 mg/L the Nycocard correlated well with the reference test, while the QuikRead underestimated concentrations above 60 mg/L. The Nycocard test seems a good candidate for CRP point-of-care testing in general practice.</description>
    </item> <item>
      <title>Euthyroid sick syndrome in meningococcal sepsis: the impact of peripheral thyroid hormone metabolism and binding proteins. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13881/</link>
      <pubDate>2005-10-01T00:00:00Z</pubDate>
      <description>CONTEXT AND OBJECTIVES: The objective of this study was to elucidate the influence of disease severity, deiodination, sulfation, thyroid hormone binding, and dopamine use on thyroid function in euthyroid sick syndrome. SETTING: The study was performed at a university-affiliated pediatric intensive care unit (PICU). DESIGN: This was an observational cohort study. PATIENTS: Sixty-nine children with meningococcal sepsis were studied. MAIN OUTCOME MEASURES: Differences in thyroid function among nonsurvivors, shock survivors, and sepsis survivors on PICU admission were the main outcome measures. RESULTS: The main study group consisted of 45 non-dopamine-treated children. All children had decreased total T3 (TT3)/rT3 ratios without elevated TSH. T4 sulfate levels were decreased in 88%. Nonsurvivors had paradoxically higher TT3/rT3 ratios than shock survivors (0.71 vs. 0.30); this ratio also correlated with shorter duration of disease (r = -0.43). TT4 and T4-binding globulin (TBG) levels declined with increasing disease severity. TBG levels correlated inversely with elastase levels (r = -0.46). Only TSH levels were significantly lower in 24 dopamine-treated children compared with non-dopamine-treated children (0.65 vs. 0.84), whereas other thyroid hormones did not significantly differ. Both higher TT3/rT3 ratios and lower TT4 levels were predictive for mortality, but this disappeared when IL-6 was entered into the regression model. CONCLUSIONS: All children with meningococcal sepsis showed signs of euthyroid sick syndrome. Alterations in peripheral thyroid hormone metabolism related inversely to the duration of disease and seemed to be enacted by profound induction of type 3 deiodinase rather than by down-regulation of type 1. Lower TT4 levels were related to increased turnover of TBG by elastase. Dopamine was found to suppress only TSH secretion, not other thyroid hormone levels, on PICU admission. Both the TT3/rT3 ratio and TT4 levels were predictive for mortality, but were not superior to IL-6.</description>
    </item> <item>
      <title>A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13704/</link>
      <pubDate>2005-07-01T00:00:00Z</pubDate>
      <description>Type II deiodinase (D2) is important in the regulation of local thyroid hormone bioactivity in certain tissues. D2 in skeletal muscle may also play a role in serum triiodothyronine (T(3)) production. In this study, we identified a polymorphism in the 5'-UTR of the D2 gene (D2-ORFa-Gly3Asp). We investigated the association of D2-ORFa-Gly3Asp, and of the previously identified D2-Thr92Ala polymorphism, with serum iodothyronine levels. D2-ORFa-Gly3Asp was identified by sequencing the 5'-UTR of 15 randomly selected individuals. Genotypes for D2-ORFa-Gly3Asp were determined in 156 healthy blood donors (age 46.3 +/- 12.2 yr) and 349 ambulant elderly men (age 77.7 +/- 3.5 yr) and related to serum iodothyronine and TSH levels. D2-ORFa-Asp(3) had an allele frequency of 33.9% in blood bank donors and was associated with serum thyroxine (T(4); Gly/Gly vs. Gly/Asp vs. Asp/Asp = 7.06 +/- 0.14 vs. 6.74 +/- 0.15 vs. 6.29 +/- 0.27 microg/dl, P = 0.01), free T(4) (1.22 +/- 0.02 vs. 1.16 +/- 0.02 vs. 1.06 +/- 0.04 ng/dl, P = 0.001), reverse T(3) (P = 0.01), and T(3)/T(4) ratio (P = 0.002) in a dose-dependent manner, but not with serum T(3) (P = 0.59). In elderly men, D2-ORFa-Asp(3) had a similar frequency but was not associated with serum iodothyronine levels. This new polymorphism in the 5'-UTR of D2 is associated with iodothyronine levels in blood donors but not in elderly men. We hypothesize that this might be explained by the decline in skeletal muscle size during aging, resulting in a relative decrease in the contribution of D2 to serum T(3) production.</description>
    </item> <item>
      <title>Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects (Article)</title>
      <link>http://repub.eur.nl/res/pub/10143/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Single nucleotide polymorphisms (SNPs) in genes involved in thyroid
      hormone metabolism may affect thyroid hormone bioactivity. We investigated
      the occurrence and possible effects of SNPs in the deiodinases (D1-D3),
      the TSH receptor (TSHR), and the T(3) receptor beta (TR beta) genes. SNPs
      were identified in public databases or by sequencing of genomic DNA from
      15 randomly selected subjects (30 alleles). Genotypes for the identified
      SNPs were determined in 156 healthy blood donors and related to plasma
      T(4), free T(4), T(3), rT(3), and TSH levels. Eight SNPs of interest were
      identified, four of which had not yet been published. Three are located in
      the 3'-untranslated region: D1a-C/T (allele frequencies, C = 66%, T =
      34%), D1b-A/G (A = 89.7%, G = 10.3%), and D3-T/G (T = 85.5%, G = 14.2%).
      Four are missense SNPs: D2-A/G (Thr92Ala, Thr = 61.2%, Ala = 38.8%),
      TSHRa-G/C (Asp36His, Asp = 99.4%, His = 0.6%), TSHRb-C/A (Pro52Thr, Pro =
      94.2%, Thr = 5.8%), and TSHRc-C/G (Asp727Glu, Asp = 90.7%, Glu = 9.3%).
      One is a silent SNP: TR beta-T/C (T = 96.8%, C = 3.2%). D1a-T was
      associated in a dose-dependent manner with a higher plasma rT(3) [CC, 0.29
      +/- 0.01; CT, 0.32 +/- 0.01; and TT, 0.34 +/- 0.02 nmol/liter (mean +/-
      SE); P = 0.017], a higher plasma rT(3)/T(4) (P = 0.01), and a lower
      T(3)/rT(3) (P = 0.003) ratio. The D1b-G allele was associated with lower
      plasma rT(3)/T(4) (P = 0.024) and with higher T(3)/rT(3) (P = 0.08)
      ratios. TSHRc-G was associated with a lower plasma TSH (CC, 1.38 +/- 0.07,
      vs. GC, 1.06 +/- 0.14 mU/liter; P = 0.04), and with lower plasma TSH/free
      T(4) (P = 0.06), TSH/T(3) (P = 0.06), and TSH/T(4) (P = 0.08) ratios. No
      associations with TSH and iodothyronine levels were found for the other
      SNPs. We have analyzed eight SNPs in five thyroid hormone pathway genes
      and found significant associations of three SNPs in two genes (D1, TSHR)
      with plasma TSH or iodothyronine levels in a normal population.</description>
    </item> <item>
      <title>Changes in globus pallidus with (pre)term kernicterus (Article)</title>
      <link>http://repub.eur.nl/res/pub/10269/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: We report serial magnetic resonance (MR) and sonographic
      behavior of globus pallidus in 5 preterm and 3 term infants with
      kernicterus and describe the clinical context in very low birth weight
      preterm infants. On the basis of this information, we suggest means of
      diagnosis and prevention. METHODS: Charts and MR and ultrasound images of
      5 preterm infants and 3 term infants with suspected bilirubin-associated
      brain damage were reviewed. Included were preterm infants with severe
      hearing loss, quadriplegic hypertonia, and abnormal hypersignal of globus
      pallidus on T2-weighted MR imaging (MRI). In 1 infant who died on day 150,
      the diagnosis was confirmed during the neonatal period. The others were
      picked up as outpatients and scanned at 12 or 22 months' corrected age.
      Three instances of term kernicterus were included for comparison of serial
      MRI in the neonatal period and early infancy: they were caused by
      glucose-6-phosphate dehydrogenase deficiency, urosepsis, and dehydration
      plus fructose 1-6 biphosphatase deficiency. RESULTS: Five preterm infants
      of 25 to 29 weeks' gestational age presented with total serum bilirubin
      (TSB) levels below exchange transfusion thresholds commonly advised. Mixed
      acidosis was present in 3 infants around the TSB peak. The
      bilirubin/albumin molar ratio was &gt;0.5 in all, in the absence of
      displacing drugs. All failed to pass bedside hearing screen tests and had
      severe hearing loss on auditory brain response testing. Symmetrical
      homogeneous hyperechogenicity of globus pallidus was the alerting feature
      in 1 infant. Globus pallidus was hyperintense on T1-weighted MR images in
      this child. The other infants presented with severe developmental delay as
      a result of dyskinetic quadriplegia and hearing loss. Globus pallidus was
      normal on T1- but hyperintense on T2-weighted MR images at 12 or 22
      months' corrected age. Subthalamic involvement was documented in coronal
      fluid attenuated inversion recovery MRI in 2 infants. The term infants
      with classical clinical presentation in the neonatal period had MR
      behavior similar to the preterms, but pallidal injury was not recognized
      with targeted sonographic examination. Their neonatal MR images
      demonstrated pallidal T1 hyperintensity and mild T2 hyperintensity.
      CONCLUSION: Acidotic very low birth weight preterm infants with low serum
      albumin levels develop MR-confirmed pallidal injury and hearing loss
      facing "accepted" TSB levels. Serial MRI documents a shift from acute
      mainly T1 hypersignal to permanent T2 hypersignal in globus pallidus
      within the late neonatal period. Subthalamic and not thalamic involvement
      helps to differentiate from ischemic or metabolic disorder. As newborns,
      these infants are rigid and have severe apnea, before developing
      hypertonic quadriplegia in infancy.</description>
    </item>
  </channel>
</rss>